Novartis wins a competitive advantage over Roche for its drug cocktail, Tafiliar and Mekinist

Novartis, the Swiss drug maker has recently come up with the results of a clinical trial study from a patient pool detected with BRAF V600E mutation-positive melanoma. Findings from the study depict that the pharmaceutical giant has nailed its primary endpoint in the initial trial. As claimed by the ESMO (European Society for Medical Oncology) Congress in Madrid, a significant reduction of 53% in the death risk and recurrence of melanoma has been observed in patients treated with Novartis’s combination therapy, Tafiliar + Mekinist, versus placebo. Undeniably, this trail win would place Novartis on a higher stand in the fiercely competitive outcome-based pharmaceutical market, especially when its cross-town rival, Roche, failed in a separate trial study with the same patient group.

The tolerability and efficacy of Tafilar in combo with Mekinist has believed to be an outset of a new era in the treatment of third stage BRAF mutation-positive melanoma. The extraordinary results from the clinical trial confirmed that this combinational therapy by Novartis has the potential to completely transform the treatment of melanoma detected patients. As per reliable sources, in this clinical trial, Novartis has already tested all these medicines in BRAF mutation infected patients who had a complete surgical resection of tumors, with an aim to observe a better response for the targeted cancer pills. In a bid to respond to the alarming call of BRAF mutations that is increasing at an exponential rate, Novartis through its recent drug trial result, plans to leave an influential impact on the overall pharmaceutical business space. In fact, statistics depict, worldwide, patients with BRAF mutations represent almost 50% of the melanoma population.

While Mekinist and Tafinlar have been witnessing an upward trend, recording a commercialization of USD 672 million in 2016, Roche’s Zelboraf sales slipped down to USD 224 million in the same year. Zelboraf application did not guarantee disease-free survival of patients suffering from terminal stage BRAF mutations, a factor that might hamper the global giant’s competitive profiling in the business scenario against Novartis. Although, it has been also reported that Zelboraf appeared to be effective for patients detected with an early stage melanoma.

Though still at a nascent stage, this clinical finding undoubtedly will allow Novartis to gain an upper hand in the competitive landscape. This clinical trial not only reflects the Swiss giants’ incessant efforts in the expansion of its business profile, but also depicts enough substantiations regarding the leading pharmaceutical firms’ inclination toward combination therapy approach against advanced high-risk skin cancer. Novartis is not the only name dealing with adjuvant melanoma treatment. Bristol-Myers Squibb’s immunotherapy drug, Opdivo has recently come up with positive results and as reported, these drugs are not restricted to be used in BRAF mutant tumors patient. Novartis' clinical trial successful win with its drug cocktail, Tafinlar, and Mekinist, is sure to open a potential new avenue in the healthcare space against skin cancer.

Novartis is expecting a regulatory approval for its new adjuvant setting by the end of this fiscal year, cite reliable sources.

About Author


Satarupa De

Satarupa develops content for Market Size Forecasters. An electrical engineer by qualification, she worked for two years in the electrical domain before switching her professional genre. Following her childhood passion, she opted for a career in writing and now pens down articles pertaining to marke...

Read More